Earningsreport

Q3/2023 9/30/2023 EPS -0.650 ZacksConsensus -0.630 ActVsEst (0.020) - Miss

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com